“Valeant Pharmaceuticals' Business Model: the Repercussions for Patients and the Health Care System”

Date: Wednesday, April 27, 2016 Time: 03:30 PM Location: Hart 216

Open in New Window

Witnesses

Panel I

  1. Berna Heyman
    Wilson Disease patient, and retired Associate Dean of Libraries
    William & Mary
  2. Dr. Frederick K. Askari, M.D. PhD
    Associate Professor, and Director, Wilson Disease Center of Excellence
    University of Michigan Health System
  3. Dr. Richard Fogel M.D., FACC, FHRS
    Chief Clinical Officer
    St. Vincent

Panel II

  1. William A. Ackman
    Founder and Chief Executive Officer, Director,
    Pershing Square Capitol Management LP,, Valeant Pharmaceuticals International, Inc.,
  2. J. Michael Pearson
    Chief Executive Officer
    Valeant Pharmaceuticals International, Inc
  3. Howard Schiller
    Director, former Chief Financial Officer, and former Interim Chief Executive Officer
    Valeant Pharmaceuticals International, Inc.,